IW 362

April 26, 2026 Viktor Zarev 0 min read
  1. Payors launch effort to standardize prior authorizations.
  2. Is AI-powered prior authorization delaying medical care? 
  3. Trump closes last of 17 deals to cut drug prices.
  4. Healthcare providers warily watch for pharma shortages. 
  5. Report: Medical lobbying groups spending more in Washington.
  6. ER patients waiting days for inpatient hospital beds. 
  7. Guest issues raise questions about academic publishing. 
  8. Should the Main Residency Match be reformed?
  9. FTC reaches pact to finally settle anesthesia roll-up complaint.
  10. Trump administrationdowngrades marijuana classification.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Cardiology April 30, 2026

Cardiac Wire’s Top Six of HRS 2026 April 30, 2026

The Heart Rhythm Society's Annual Meeting for 2026 electrified Chicago with talks of the latest EP tech, rhythm management debates, and insights into where remote patient monitoring is headed. Here are Cardiac Wire’s top-six takeaways from electrophysiology’s biggest weekend of the year.